Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.96 USD | -3.86% | -9.88% | -30.29% |
Apr. 09 | UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating | MT |
Apr. 03 | Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing | MT |
Financials (USD)
Sales 2024 * | 65.76M | Sales 2025 * | 121M | Capitalization | 2.22B |
---|---|---|---|---|---|
Net income 2024 * | -411M | Net income 2025 * | -442M | EV / Sales 2024 * | 12.3 x |
Net cash position 2024 * | 1.41B | Net cash position 2025 * | 1.17B | EV / Sales 2025 * | 8.64 x |
P/E ratio 2024 * |
-5.72
x | P/E ratio 2025 * |
-5.67
x | Employees | 445 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.18% |
Latest transcript on Denali Therapeutics Inc.
1 day | -3.86% | ||
1 week | -9.88% | ||
Current month | -27.10% | ||
1 month | -24.71% | ||
3 months | -13.02% | ||
6 months | -23.83% | ||
Current year | -30.29% |
Managers | Title | Age | Since |
---|---|---|---|
Alexander Schuth
FOU | Founder | 50 | 13-10-13 |
Ryan Watts
FOU | Founder | 48 | 13-10-13 |
Joe Lewcock
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Vicki Sato
CHM | Chairman | 75 | 15-03-31 |
Jay Flatley
BRD | Director/Board Member | 71 | 15-03-31 |
David Schenkein
BRD | Director/Board Member | 66 | 15-03-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.31% | 0 M€ | 0.00% | - | |
0.31% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 14.96 | -3.86% | 1,140,531 |
24-04-24 | 15.56 | -3.41% | 944,425 |
24-04-23 | 16.11 | +0.75% | 1,080,081 |
24-04-22 | 15.99 | -0.06% | 3,056,993 |
24-04-19 | 16 | -3.61% | 1,479,992 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.29% | 2.22B | |
-2.26% | 104B | |
+1.41% | 97.42B | |
+0.79% | 22.2B | |
-17.84% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-17.63% | 15.06B | |
+4.55% | 13.98B | |
+32.11% | 11.66B |
- Stock Market
- Equities
- DNLI Stock